TY - JOUR
T1 - A prospective multicentre REFCOR study of 470 cases of head and neck Adenoid cystic carcinoma
T2 - epidemiology and prognostic factors
AU - Atallah, Sarah
AU - Casiraghi, Odile
AU - Fakhry, Nicolas
AU - Wassef, Michel
AU - Uro-Coste, Emmanuelle
AU - Espitalier, Florent
AU - Sudaka, Anne
AU - Kaminsky, Marie Christine
AU - Dakpe, Stéphanie
AU - Digue, Laurence
AU - Bouchain, Olivier
AU - Morinière, Sylvain
AU - Hourseau, Muriel
AU - Bertolus, Chloé
AU - Jegoux, Franck
AU - Thariat, Juliette
AU - Calugaru, Valentin
AU - Schultz, Philippe
AU - Philouze, Pierre
AU - Mauvais, Olivier
AU - Righini, Christian A.
AU - Badoual, Cécile
AU - Saroul, Nicolas
AU - Goujon, Jean Michel
AU - Marie, Jean Paul
AU - Taouachi, Rabah
AU - Brenet, Esteban
AU - Aupérin, Anne
AU - Baujat, Bertrand
N1 - Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/5/1
Y1 - 2020/5/1
N2 - Background: Adenoid cystic carcinoma (ACC) accounts for 1% of malignant head and neck tumours [1] and 10% of salivary glands malignant tumours. The main objective of our study is to investigate the prognostic factors influencing the event-free survival (EFS) of patients with ACC. Patients and methods: A multicentre prospective study was conducted from 2009 to 2018. All 470 patients with ACC whose survival data appear in the REFCOR database were included in the study. The main judgement criterion was EFS. Both a bivariate survival analysis using log-rank test and a multivariate using Cox model were performed using the R software. Results: Average age was 55 years. Females accounted for 59.4% of the cohort. The body mass index (BMI) was normal in 86% of cases. Tumours were located in minor salivary glands in 60% of cases. T3/T4 stages represented 58%; 89% of patients were cN0. histological grade III was observed on 21% of patients. The EFS and overall 5-year survival rates were 50% and 85%, respectively. After adjustment, the most significant pejorative prognostic factors were age ≥65 years (hazard ratio [HR] = 1.67), BMI<16.5 (HR = 2.62), and lymph node invasion cN (HR = 2.08). Conclusion: Age, BMI and N stage are the three main clinical prognostic factors determining EFS identified in this prospective series of patients with ACC. Such findings open new research perspectives on the influence of these components on initial patient care.
AB - Background: Adenoid cystic carcinoma (ACC) accounts for 1% of malignant head and neck tumours [1] and 10% of salivary glands malignant tumours. The main objective of our study is to investigate the prognostic factors influencing the event-free survival (EFS) of patients with ACC. Patients and methods: A multicentre prospective study was conducted from 2009 to 2018. All 470 patients with ACC whose survival data appear in the REFCOR database were included in the study. The main judgement criterion was EFS. Both a bivariate survival analysis using log-rank test and a multivariate using Cox model were performed using the R software. Results: Average age was 55 years. Females accounted for 59.4% of the cohort. The body mass index (BMI) was normal in 86% of cases. Tumours were located in minor salivary glands in 60% of cases. T3/T4 stages represented 58%; 89% of patients were cN0. histological grade III was observed on 21% of patients. The EFS and overall 5-year survival rates were 50% and 85%, respectively. After adjustment, the most significant pejorative prognostic factors were age ≥65 years (hazard ratio [HR] = 1.67), BMI<16.5 (HR = 2.62), and lymph node invasion cN (HR = 2.08). Conclusion: Age, BMI and N stage are the three main clinical prognostic factors determining EFS identified in this prospective series of patients with ACC. Such findings open new research perspectives on the influence of these components on initial patient care.
KW - Adenoid cystic carcinoma
KW - Event-free survival
KW - Prognostic factors
KW - REFCOR
UR - http://www.scopus.com/inward/record.url?scp=85081605975&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2020.01.023
DO - 10.1016/j.ejca.2020.01.023
M3 - Article
C2 - 32171628
AN - SCOPUS:85081605975
SN - 0959-8049
VL - 130
SP - 241
EP - 249
JO - European Journal of Cancer
JF - European Journal of Cancer
ER -